サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1709462

神経保護の世界市場：製品種類別・適応症別・作用機序別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)

Neuroprotection Market, By Product Type, By Disease Indication, By Mechanism of Action, By End User, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 309 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
神経保護の世界市場：製品種類別・適応症別・作用機序別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)
出版日: 2025年03月04日
発行: AnalystView Market Insights
ページ情報: 英文 309 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

神経保護市場の市場規模は2024年に340億9,243万米ドルとなり、2025年から2032年にかけてCAGR 7.42％で拡大しました。

この市場の成長を牽引しているのは、神経疾患の有病率の増加、医学研究の進歩、効果的な治療に対する需要の高まりです。さらに、世界人口の高齢化は、神経変性疾患がより一般的になるにつれて、市場をさらに活性化させる。各企業は革新的なソリューションに多額の投資を行っており、神経保護における治療選択肢の拡大につながっています。

神経保護の市場力学

神経変性疾患の早期診断に向けたバイオマーカー探索の進展。

バイオマーカー探索の進歩は神経変性疾患の早期診断に重要な役割を果たし、神経保護市場を大きく牽引しています。バイオマーカーは神経障害を発症時に発見するのに役立ち、より早期で効果的な介入を可能にします。バイオマーカーによって特定の疾患サブタイプが特定され、進行が予測されるため、こうした発見によって個別化治療アプローチが促進されます。診断精度の向上は、タイムリーな治療とより良い管理を保証することにより、医療コストを削減することができます。

学術機関や研究機関は、画期的な進歩を促進する共同研究によって、この分野をリードしています。例えば、米国国立加齢研究所（NIA）はアルツハイマー病のバイオマーカー研究に積極的に資金を提供しており、いくつかの有望な診断マーカーの開発につながっています。NIAによれば、年間3億米ドル以上がアルツハイマー病の研究に割り当てられており、その多くがバイオマーカーの開発に焦点を当てています。これらの開発は、診断精度を高めるだけでなく、神経変性治療における精密医療という広範な動向を支えています。

神経保護市場：主な考察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2025-2032年）に約7.42%のCAGRで毎年成長すると推定されます。

製品種類別では、市場セグメンテーションは2024年に最大の市場シェアを示すと予測されています。

適応症別では、アルツハイマー病が2024年の主要な適応症でした。

作用機序別では、2024年に抗酸化物質が主要な作用機序でした。

エンドユーザー別では、病院が2024年の主要エンドユーザーでした。

地域別では、北米が2024年に収益を生み出す主要市場です。

神経保護市場：セグメンテーション分析

世界の神経保護市場は、製品種類、適応症、作用機序、エンドユーザー、地域によって区分されます。

市場は製品種類によって2つのカテゴリーに分けられます：薬剤と装置です。神経保護市場では、薬剤が最も重要なセグメントです。アルツハイマー病、パーキンソン病、多発性硬化症などの神経疾患や症状の治療に直接的な役割を果たすため、市場を独占しています。神経保護薬を含む薬剤は、疾患の進行を遅らせ、ニューロンを損傷から守り、患者の生活の質を改善するように設計されています。この分野は、現在進行中の研究、臨床試験、規制当局の承認から利益を得ており、新規の医薬品治療に対する需要を牽引しています。神経科学における進歩がより効果的な治療につながることから、神経保護薬の市場は今後も成長を続けると予想されます。

市場は適応症別に6つのカテゴリーに分類されます：パーキンソン病、アルツハイマー病、脳卒中、多発性硬化症、筋萎縮性側索硬化症（ALS）、外傷性脳損傷（TBI）、その他です。神経保護市場では、アルツハイマー病が最も重要な疾患適応症です。世界の有病率の高さと高齢化人口の増加により、最大のシェアを占めています。アルツハイマー病は広範な神経変性の引き金となり、進行を遅らせることを目的とした神経保護療法に対する大きな需要を生み出しています。医薬品開発における継続的な進歩や、効果的な治療法の発見に対する関心の高まりが、このセグメントを前進させています。革新的な治療法の必要性が高まる中、アルツハイマー病は研究者や製薬企業にとって依然として焦点となっています。

神経保護市場：地域別分析

北米の神経保護市場は、人口の高齢化、アルツハイマー病、パーキンソン病、多発性硬化症などの神経変性疾患の有病率の増加、バイオテクノロジーと医薬品の進歩などを背景に、大きな成長を遂げています。米国が最大のシェアを占めているのは、強力な医療インフラ、充実した研究資金、治療ソリューションに対する高い需要によるものです。カナダも、神経保護研究開発への投資拡大で市場に貢献しています。さらに、初期段階の介入や予防治療、新興の薬物療法への注目も高まっています。政府の取り組みや学術機関と民間企業との連携により、神経保護剤の技術革新が進んでいます。しかし、高い薬剤開発コストや規制上のハードルといった課題も残っています。にもかかわらず、市場の見通しは依然として楽観的であり、業界の主要企業はアンメット・メディカル・ニーズに対応するための新たな治療戦略を模索しています。

米国は北米の神経保護市場において支配的な国であるが、その主な理由は先進的な医療制度、高い研究開発レベル、医療技術革新に対する多額の政府資金です。同国には神経変性疾患に特化した主要バイオテクノロジー企業や製薬企業が多数存在し、神経保護療法の急速な開発と商業化に貢献しています。さらに、米国では人口が多く高齢化が進んでいるため、治療に対する需要が高まっており、市場成長の主な要因となっています。

神経保護市場：競合情勢

神経保護市場の競合情勢は、製薬企業、バイオテクノロジー企業、研究機関の間の激しい敵対関係によって特徴付けられ、いずれも神経疾患の効果的な治療法の開発を競っています。Biogen、Novartis、Eli Lillyなどの大手企業は、アルツハイマー病やパーキンソン病などの神経変性疾患において確立されたポートフォリオを有しており、優位を占めています。各社は、神経炎症や神経再生のような新たなメカニズムを標的とした革新的な創薬に注力しています。また、遺伝子治療や幹細胞研究のような先端技術を活用するために、大手製薬企業と中小バイオテクノロジー企業との共同研究も行われています。

神経変性疾患の有病率の増加と治療法の改善の必要性が、市場シェアをめぐる熾烈な競争を促しています。規制当局の承認プロセスや研究開発費の高騰が複雑さを増し、多大なリソースと専門知識を持つ少数の支配的なプレーヤーが存在することになります。新規参入企業は、差別化を図るためにニッチな領域や画期的な治療法を常に模索しています。

目次

第1章 神経保護市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 神経保護の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 神経保護市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 神経保護市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 神経保護の市場情勢

  • 神経保護の市場シェア分析 (2024年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 神経保護市場：製品種類別

  • 概要
    • セグメント別シェア分析：製品種類別
    • 薬剤
      • 抗酸化物質
      • 抗炎症薬
      • カルシウムチャネル遮断薬
      • フリーラジカルスカベンジャー
    • 装置

第8章 神経保護市場：適応症別

  • 概要
    • セグメント別シェア分析：適応症別
    • パーキンソン病
    • アルツハイマー病
    • 脳卒中
    • 多発性硬化症
    • 筋萎縮性側索硬化症（ALS）
    • 外傷性脳損傷（TBI）
    • その他

第9章 神経保護市場：作用機序別

  • 概要
    • セグメント別シェア分析：作用機序別
    • 抗酸化物質
    • ミトコンドリア保護
    • 炎症調節
    • カルシウム調節
    • 神経新生刺激
    • 遺伝子治療ベース

第10章 神経保護市場：エンドユーザー別

  • 概要
    • セグメント別シェア分析：エンドユーザー別
    • 病院
    • 診療所
    • 研究機関
    • 在宅医療

第11章 神経保護市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ（LATAM）
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ（MEA）
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析：神経保護業界

  • 競合ダッシュボード
    • 競合ベンチマーク
    • 競合ポジショニング
  • 企業プロファイル
    • Biogen Inc.
    • Eli Lilly and Co.
    • Novartis AG
    • Roche Holding AG
    • Merck &Co.
    • Pfizer Inc.
    • Amgen Inc.
    • AbbVie Inc.
    • Johnson &Johnson
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Lundbeck A/S
    • GlaxoSmithKline（GSK）
    • AstraZeneca plc
    • Eisai Co., Ltd.
    • Neurocrine Biosciences, Inc.
    • Axovant Gene Therapies

第13章 AnalystViewの全方位的分析

目次
Product Code: ANV4932

REPORT HIGHLIGHT

Neuroprotection Market size was valued at US$ 34,092.43 Million in 2024, expanding at a CAGR of 7.42% from 2025 to 2032.

The neuroprotection market refers to the industry focused on developing therapies and products aimed at protecting the nervous system, particularly the brain and spinal cord, from damage caused by diseases, injuries, or aging. This market addresses conditions such as Alzheimer's disease, Parkinson's disease, stroke, multiple sclerosis, and traumatic brain injuries. Neuroprotective treatments can involve drug therapies, antioxidants, neurotrophic factors, and other interventions that help prevent or reduce neuronal damage.

The growth of this market is driven by the increasing prevalence of neurological disorders, advances in medical research, and the rising demand for effective treatments. Additionally, the aging global population further fuels the market as neurodegenerative diseases become more common. Companies are heavily investing in innovative solutions, leading to an expanding range of therapeutic options in neuroprotection.

Neuroprotection Market- Market Dynamics

Advancements in biomarker discovery for early-stage neurodegenerative disease diagnosis.

Advancements in biomarker discovery play a critical role in the early diagnosis of neurodegenerative diseases, significantly driving the neuroprotection market. Biomarkers help detect neurological disorders at their onset, enabling earlier and more effective intervention, which is crucial for improving patient outcomes. These discoveries facilitate personalized treatment approaches, as biomarkers can identify specific disease subtypes and predict progression. Enhanced diagnostic precision can reduce healthcare costs by ensuring timely therapies and better management.

Academic institutions and research organizations are leading the charge, with collaborations fostering breakthroughs. For instance, the National Institute on Aging (NIA) in the U.S. is actively funding biomarker research for Alzheimer's disease, which has led to the development of several promising diagnostic markers. According to the NIA, over $300 million is allocated annually toward Alzheimer's research, much of which focuses on biomarker advancements. These developments not only enhance diagnostic accuracy but also support the broader trend of precision medicine in neurodegenerative care.

Neuroprotection Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.42% over the forecast period (2025-2032)

Based on product type segmentation, Medications was predicted to show maximum market share in the year 2024

Based on Disease Indication segmentation, Alzheimer's disease was the leading Disease Indication in 2024

Based on Mechanism of Action segmentation, Antioxidants was the leading Mechanism of Action in 2024

Based on End-User segmentation, Hospitals was the leading End-User in 2024

On the basis of region, North America was the leading revenue generator in 2024

Neuroprotection Market- Segmentation Analysis:

The Global Neuroprotection Market is segmented on the basis of Product Type, Disease Indication, Mechanism of Action, End User, and Region.

The market is divided into two categories based on product type: Medication and Devices. In the neuroprotection market, medications are the most significant segment. They dominate the market due to their direct role in treating neurological diseases and conditions like Alzheimer's, Parkinson's, and multiple sclerosis. Medications, including neuroprotective drugs, are designed to slow disease progression, protect neurons from damage, and improve patients' quality of life. This segment benefits from ongoing research, clinical trials, and regulatory approvals, driving demand for novel pharmaceutical treatments. The market for neuroprotective medications is expected to continue growing as advancements in neuroscience lead to more effective therapies.

The market is divided into six categories based on Disease Indication: Parkinson's Disease, Alzheimer's Disease, Stroke, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Others. In the neuroprotection market, Alzheimer's disease is the most significant disease indication. It holds the largest share due to the high prevalence of the disease worldwide and the increasing aging population. Alzheimer's triggers widespread neurodegeneration, creating a substantial demand for neuroprotective therapies aimed at slowing its progression. Ongoing advancements in drug development and the increasing focus on finding effective treatments have propelled this segment forward. As the need for innovative treatments grows, Alzheimer's disease remains a focal point for researchers and pharmaceutical companies.

Neuroprotection Market- Geographical Insights

The North American neuroprotection market is experiencing significant growth, driven by an aging population, increasing prevalence of neurodegenerative diseases like Alzheimer's, Parkinson's, and multiple sclerosis, and advances in biotechnology and pharmaceuticals. The U.S. holds the largest share, owing to strong healthcare infrastructure, substantial research funding, and a high demand for therapeutic solutions. Canada is also contributing to the market with growing investments in neuroprotective research and development. Furthermore, there is a rising focus on early-stage interventions and preventative treatments, as well as emerging drug therapies. Government initiatives and collaborations between academic institutions and private sectors are enhancing innovation in neuroprotective agents. However, challenges such as high drug development costs and regulatory hurdles remain. Despite this, the market outlook remains optimistic, with key players in the industry exploring novel treatment strategies to address unmet medical needs.

The United States is the dominant country in the North American neuroprotection market, largely due to its advanced healthcare system, high level of research and development, and substantial government funding for medical innovation. The country is home to many leading biotech and pharmaceutical companies focused on neurodegenerative diseases, contributing to the rapid development and commercialization of neuroprotective therapies. Additionally, the large and aging population in the U.S. presents a growing demand for treatments, making it a key driver of market growth.

Neuroprotection Market- Competitive Landscape:

The competitive landscape of the neuroprotection market is characterized by intense rivalry among pharmaceutical companies, biotech firms, and research institutions, all vying to develop effective treatments for neurological disorders. Major players such as Biogen, Novartis, and Eli Lilly dominate with established portfolios in neurodegenerative diseases like Alzheimer's and Parkinson's. Companies are focusing on innovative drug discovery, targeting new mechanisms like neuroinflammation and neuroregeneration. The market also sees collaborations between large pharmaceutical firms and smaller biotech companies to leverage advanced technologies like gene therapy and stem cell research.

The increasing prevalence of neurodegenerative diseases and the need for improved treatments drive fierce competition for market share. Regulatory approval processes and the high cost of R&D add layers of complexity, leading to a few dominant players with significant resources and expertise. New entrants are constantly looking for niche areas and breakthrough therapies to differentiate themselves.

Recent Developments:

In November 2023, the US Food and Drug Administration (FDA) met with BrainStorm Cell Therapeutics to discuss NurOwn, a device with the potential to alleviate symptoms of ALS. The meeting discussed the overall protocol design of a potential confirmatory Phase III trial.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROPROTECTION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Biogen Inc.
  • Eli Lilly and Co.
  • Novartis AG
  • Roche Holding AG
  • Merck & Co.
  • Pfizer Inc.
  • Amgen Inc.
  • AbbVie Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Lundbeck A/S
  • GlaxoSmithKline (GSK)
  • AstraZeneca plc
  • Eisai Co., Ltd.
  • Neurocrine Biosciences, Inc.
  • Axovant Gene Therapies

GLOBALNEUROPROTECTION MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Medication
  • Antioxidants
  • Anti-inflammatory drugs
  • Calcium channel blockers
  • Free radical scavengers
  • Devices

GLOBAL NEUROPROTECTION MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Parkinson's Disease
  • Alzheimer's Disease
  • Stroke
  • Multiple Sclerosis
  • Amyotrophic Lateral Sclerosis (ALS)
  • Traumatic Brain Injury (TBI)
  • Others

GLOBAL NEUROPROTECTION MARKET, BY MECHANISM OF ACTION- MARKET ANALYSIS, 2019 - 2032

  • Antioxidants
  • Mitochondrial Protection
  • Inflammation Modulation
  • Calcium Regulation
  • Neurogenesis Stimulation
  • Gene Therapy-Based

GLOBAL NEUROPROTECTION MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Research Institutes
  • Home Care Settings

GLOBAL NEUROPROTECTION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuroprotection Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuroprotection Market Snippet by Product Type
    • 2.1.2. Neuroprotection Market Snippet by Disease Indication
    • 2.1.3. Neuroprotection Market Snippet by Mechanism of Action
    • 2.1.4. Neuroprotection Market Snippet by End User
    • 2.1.5. Neuroprotection Market Snippet by Country
    • 2.1.6. Neuroprotection Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuroprotection Key Market Trends

  • 3.1. Neuroprotection Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuroprotection Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuroprotection Market Opportunities
  • 3.4. Neuroprotection Market Future Trends

4. Neuroprotection Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuroprotection Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Neuroprotection Market Landscape

  • 6.1. Neuroprotection Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuroprotection Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Medication
      • 7.1.2.1. Antioxidants
      • 7.1.2.2. Anti-inflammatory drugs
      • 7.1.2.3. Calcium channel blockers
      • 7.1.2.4. Free radical scavengers
    • 7.1.3. Devices

8. Neuroprotection Market - By Disease Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
    • 8.1.2. Parkinson's Disease
    • 8.1.3. Alzheimer's Disease
    • 8.1.4. Stroke
    • 8.1.5. Multiple Sclerosis
    • 8.1.6. Amyotrophic Lateral Sclerosis (ALS)
    • 8.1.7. Traumatic Brain Injury (TBI)
    • 8.1.8. Others

9. Neuroprotection Market - By Mechanism of Action

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Mechanism of Action, 2024 & 2032 (%)
    • 9.1.2. Antioxidants
    • 9.1.3. Mitochondrial Protection
    • 9.1.4. Inflammation Modulation
    • 9.1.5. Calcium Regulation
    • 9.1.6. Neurogenesis Stimulation
    • 9.1.7. Gene Therapy-Based

10. Neuroprotection Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Research Institutes
    • 10.1.5. Home Care Settings

11. Neuroprotection Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Neuroprotection Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Neuroprotection Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Neuroprotection Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Neuroprotection Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Neuroprotection Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Neuroprotection Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Biogen Inc.
    • 12.2.2. Eli Lilly and Co.
    • 12.2.3. Novartis AG
    • 12.2.4. Roche Holding AG
    • 12.2.5. Merck & Co.
    • 12.2.6. Pfizer Inc.
    • 12.2.7. Amgen Inc.
    • 12.2.8. AbbVie Inc.
    • 12.2.9. Johnson & Johnson
    • 12.2.10. Sanofi S.A.
    • 12.2.11. Teva Pharmaceutical Industries Ltd.
    • 12.2.12. Takeda Pharmaceutical Company Limited
    • 12.2.13. Lundbeck A/S
    • 12.2.14. GlaxoSmithKline (GSK)
    • 12.2.15. AstraZeneca plc
    • 12.2.16. Eisai Co., Ltd.
    • 12.2.17. Neurocrine Biosciences, Inc.
    • 12.2.18. Axovant Gene Therapies

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us